NEW Dividend Portfolio Tracker (DRIPTracker) is Now Live!
Add your stocks and see every dividend they pay you — dates, amounts, and reinvested shares.
Start Free »

DNA | NYSE

$11.36 -$1.64 | -12.62%
TREND SIGNAL:Signal available — unlock to view |2026-10-08

Company Overview:

Market Cap: $875.42M
Trailing PE: N/A
FWD PE: —
Payout Ratio (TTM): —
52-Week Range: $5.37 - $18.22

5.5 Year DNA Performance Metrics:

Total Return (with DRIP): -97.2% (-47.78% CAGR)
Total Return (no DRIP): -97.2% (-47.78% CAGR)
Share Price: -97.2% (-47.78% CAGR)
Yield on Cost (with DRIP): —
Total Invested: $10,000
Total Value (with DRIP): $281
Total Return $ (with DRIP): -$9,719
DNA Total Return
1M 3M 6M YTD 1Y 3Y 5Y 10Y
DNA Price Chart
1M 3M 6M YTD 1Y 3Y 5Y 10Y All

Unlock All Reports & Research Dividend Stocks like a BOSS!

Get 3 Months Free with Annual Plan
PRO
$171 ($14.25/mo) $102.60/yr ($8.55/mo)
7-day free trial
  • Unlimited Portfolio Tracker
  • Portfolio - Lots/Sales/Dividends
  • Portfolio Auto-DRIP
  • Buy/Sell Signals Dashboard
  • Stock Fundamentals
  • Compare Stocks Side-by-Side
  • Revenue & EPS Estimates
  • DCF Valuation Modeling
Try it free for 7 days
Combined 55% Lifetime Discount
Most Popular
PREMIUM
$288 ($24/mo) $172.80/yr ($14.40/mo)
7-day free trial
  • Everything in Pro
  • YieldMax PNL Tracker
  • YieldMax NAV Erosion Alerts
  • YM ETFs Trend Signals
  • 9/21 EMA Trend Signals
  • Stocks Dashboard
Try it free for 7 days
Combined 55% Lifetime Discount
ULTRA
$576 ($48/mo) $345.60/yr ($28.80/mo)
7-day free trial
  • Everything in Premium
  • 15min & 1hr Intraday Signals
  • Group & weekly ETF estimates
  • YouTuber Mode
  • Trades summary + CSV export
  • Priority data & support
Try it free for 7 days
Combined 55% Lifetime Discount

DNA Financials: Earnings, Revenue, Cash Flow, Ebitda, Cash/Debt, Shares Float, etc:

DNA - Revenue
DNA Revenue CAGR:1Y: -59.37%2Y: -40.12%5Y: -14.31%10Y: 0.00%
DNA - Earnings Per Share (EPS)
DNA EPS CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%
DNA - Net Income
🔓 See the full chart40% off right now · 7-day free trial
DNA Net Income CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%
DNA - EBITDA
🔓 See the full chart40% off right now · 7-day free trial
DNA EBITDA CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%
DNA - Free Cash Flow
🔓 See the full chart40% off right now · 7-day free trial
DNA Free Cash Flow CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%
DNA - Free Cash Flow / Share
🔓 See the full chart40% off right now · 7-day free trial
DNA Free Cash Flow / Share CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%
DNA - Operating Income
🔓 See the full chart40% off right now · 7-day free trial
DNA Operating Income CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%
DNA - Gross Profit
🔓 See the full chart40% off right now · 7-day free trial
DNA Gross Profit CAGR:1Y: -46.99%2Y: -34.12%5Y: -7.02%10Y: 0.00%
DNA - Shares Outstanding
🔓 See the full chart40% off right now · 7-day free trial
DNA Shares Outstanding CAGR:1Y: 13.19%2Y: 9.94%5Y: 13.96%10Y: 0.00%
DNA - Share Buybacks
🔓 See the full chart40% off right now · 7-day free trial
DNA Share Buybacks CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%
DNA - Stock-Based Comp
🔓 See the full chart40% off right now · 7-day free trial
DNA Stock-Based Comp CAGR:1Y: -65.86%2Y: -54.78%5Y: 0.00%10Y: 0.00%
DNA - Expenses
🔓 See the full chart40% off right now · 7-day free trial
DNA Expenses CAGR:1Y: 6,792.11%2Y: -68.87%5Y: -35.81%10Y: 0.00%
DNA - Revenue vs Net Income
🔓 See the full chart40% off right now · 7-day free trial
DNA - EPS vs FCF / Share
🔓 See the full chart40% off right now · 7-day free trial
DNA - EPS vs PE Ratio
🔓 See the full chart40% off right now · 7-day free trial
DNA - FCF vs FCF / Share
🔓 See the full chart40% off right now · 7-day free trial
DNA - FCF vs Stock Based Comp
🔓 See the full chart40% off right now · 7-day free trial
DNA - Cash & Debt
🔓 See the full chart40% off right now · 7-day free trial
DNA - Revenue by Segment
🔓 See the full chart40% off right now · 7-day free trial
DNA Revenue CAGR:1Y: -59.37%2Y: -40.12%5Y: -14.31%10Y: 0.00%

Revenue, EPS, Net Income & Ebitda - Estimates VS Actual:

DNA - REVENUE: Actual + Estimates
🔓 See the full chart40% off right now · 7-day free trial
DNA Actual Revenue CAGR:1Y: -59.37%2Y: -40.12%5Y: -14.31%10Y: 0.00%
DNA - EPS: Actual + Estimates
🔓 See the full chart40% off right now · 7-day free trial
DNA Actual EPS CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%
DNA - NET INCOME: Actual + Estimates
🔓 See the full chart40% off right now · 7-day free trial
DNA Actual Net Income CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%
DNA - EBITDA: Actual + Estimates
🔓 See the full chart40% off right now · 7-day free trial
DNA Actual EBITDA CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%

Ratios, Profit Margins & Return on Capital:

DNA - Net Profit Margin
🔓 See the full chart40% off right now · 7-day free trial
DNA Net Profit Margin CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%
DNA - Gross Profit Margin
🔓 See the full chart40% off right now · 7-day free trial
DNA Gross Profit Margin CAGR:1Y: 30.45%2Y: 10.00%5Y: 8.51%10Y: 0.00%
DNA - Price to Earnings
🔓 See the full chart40% off right now · 7-day free trial
DNA Price to Earnings CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%
DNA - Price To Sales Ratio
🔓 See the full chart40% off right now · 7-day free trial
DNA Price To Sales Ratio CAGR:1Y: 145.38%2Y: 60.79%5Y: -36.47%10Y: 0.00%
DNA - Return on Capital Employed
🔓 See the full chart40% off right now · 7-day free trial
DNA Return on Capital Employed CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%
DNA - Return on Invested Capital
🔓 See the full chart40% off right now · 7-day free trial
DNA Return on Invested Capital CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%

Compare stocks side-by-side

Projected Future Returns & Dividends for DNA

Based on past 5.5-year performance, here are DNA growth metrics:

Share price CAGR of -47.78%
Dividend CAGR of +0%

Using DNA CAGR metrics, we can estimate that your initial $10000 investment, over the next 10 years, should grow as follows:

DNA (DRIP)DNA - No DRIP
Current Price$11.36$11.36
Start Shares880.28880.28
Start Value$10,000$10,000
  
After 10 years:
Final Share Count880.28880.28
Dividends Payment$0.00$0.00
Annual Dividends$0$0
Yield on cost0.00%0.00%
Share Price$0.02$11.36
Total Dividends$0$0
Final Value$15$10,000

Estimated Future Value + Dividends - DNA

NOTE: Above numbers are our estimate based on DNA's Dividend and Price CAGR over past 5.5 years. These numbers should only be considered as "potential future returns"! DRIP assumes reinvesting dividends; No-DRIP assumes collecting dividends as cash.

We cannot guarantee that your actual returns will meet these estimates.

Get the best Dividend Stock Research Tools:

Get 3 Months Free with Annual Plan
PRO
$171 ($14.25/mo) $102.60/yr ($8.55/mo)
7-day free trial
  • Unlimited Portfolio Tracker
  • Portfolio - Lots/Sales/Dividends
  • Portfolio Auto-DRIP
  • Buy/Sell Signals Dashboard
  • Stock Fundamentals
  • Compare Stocks Side-by-Side
  • Revenue & EPS Estimates
  • DCF Valuation Modeling
Try it free for 7 days
Combined 55% Lifetime Discount
Most Popular
PREMIUM
$288 ($24/mo) $172.80/yr ($14.40/mo)
7-day free trial
  • Everything in Pro
  • YieldMax PNL Tracker
  • YieldMax NAV Erosion Alerts
  • YM ETFs Trend Signals
  • 9/21 EMA Trend Signals
  • Stocks Dashboard
Try it free for 7 days
Combined 55% Lifetime Discount
ULTRA
$576 ($48/mo) $345.60/yr ($28.80/mo)
7-day free trial
  • Everything in Premium
  • 15min & 1hr Intraday Signals
  • Group & weekly ETF estimates
  • YouTuber Mode
  • Trades summary + CSV export
  • Priority data & support
Try it free for 7 days
Combined 55% Lifetime Discount

Company Info

Ginkgo Bioworks Holdings, Inc. (DNA) had its IPO on 2021-04-19, and is traded on NYSE stock exchange.

Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops a platform for cell engineering in the United States. It operates through the Cell Engineering and Biosecurity segments. The company offers cell engineering research and development solutions, as well as cell engineering tools comprising functional genomics, antibody developability, and small molecule developability, artificial intelligence models, and reconfigurable automation cart systems on its platform for use in the research, development, and commercialization of engineered organisms and derived products. It also provides biomonitoring and bioinformatics support services through Canopy, which generates genomic data from strategically positioned nodes through biomonitoring programs; and Horizon, a digital surveillance, analytics, and insights platform that detects and monitors biothreats. In addition, the company offers genetic medicine R&D, protein engineering, bioprocess development, crop nutrition and protection solutions, and plant trait optimization. The company serves pharmaceutical and biotechnology, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

DNA website: https://www.ginkgobioworks.com


Get Full Access to All Reports with DRIPCalc PRO

Get 3 Months Free with Annual Plan
PRO
$171 ($14.25/mo) $102.60/yr ($8.55/mo)
7-day free trial
  • Unlimited Portfolio Tracker
  • Portfolio - Lots/Sales/Dividends
  • Portfolio Auto-DRIP
  • Buy/Sell Signals Dashboard
  • Stock Fundamentals
  • Compare Stocks Side-by-Side
  • Revenue & EPS Estimates
  • DCF Valuation Modeling
Try it free for 7 days
Combined 55% Lifetime Discount
Most Popular
PREMIUM
$288 ($24/mo) $172.80/yr ($14.40/mo)
7-day free trial
  • Everything in Pro
  • YieldMax PNL Tracker
  • YieldMax NAV Erosion Alerts
  • YM ETFs Trend Signals
  • 9/21 EMA Trend Signals
  • Stocks Dashboard
Try it free for 7 days
Combined 55% Lifetime Discount
ULTRA
$576 ($48/mo) $345.60/yr ($28.80/mo)
7-day free trial
  • Everything in Premium
  • 15min & 1hr Intraday Signals
  • Group & weekly ETF estimates
  • YouTuber Mode
  • Trades summary + CSV export
  • Priority data & support
Try it free for 7 days
Combined 55% Lifetime Discount
Loading signals…

DCF Model — DNA

Value from:
Pay up to today
—
vs current price $11.36
—
Cash flow & implied price by year

FCF is negative or missing for this company (common for banks) — the model discounts EPS instead.

EPS is negative or missing for this company — Simple mode uses free cash flow per share instead.

Free cash flow today
—
grows for the next years
Then mature
—
every future dollar counted back to today
Pile of today-dollars
—
÷ shares
Implied price path
YearFCFImplied price
Sensitivity — fair value: growth ↓ × target return →